ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ALN-AGT01 RVR

Its studies are mostly in Hypertension, led by Alnylam Pharmaceuticals.

Furthest: phase 2, since Apr 22, 20262 company-led studies, 1 open or runningNext primary completion: Apr 1, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alnylam Pharmaceuticals21 open or runningphase 2since Apr 22, 2026Oct 29, 2024Apr 1, 2028phase 2 · NCT07553442

Also a collaborator on its studies: Hoffmann-La Roche.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06675565 · 42 enrolled · Canada
  2. Apr 22, 2026Phase 2 study in HypertensionPhase 2 reachedNCT07553442 · 93 planned · United States

Ahead

  1. Apr 1, 2028Primary completion: phase 2 study in HypertensionNCT07553442

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07553442Hypertension · United States2RecruitingApr 1, 202893
NCT06675565Healthy Volunteers · Canada1CompletedSep 8, 202542

How it is read

Names in the registry

  • “ALN-AGT01 RVR”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.